Nymox Pharmaceutical Corporation Partners with KlinLab Ltd. for Alzheimer's Disease Diagnostic Test Distribution

Strategic Insights -

Nymox Pharmaceutical Corporation has formed a strategic partnership with KlinLab Ltd., a Czech clinical laboratory company, to make its AlzheimAlert product available to physicians throughout the Czech Republic for the diagnosis of Alzheimer disease. This agreement marks a significant step forward in the distribution of the AlzheimAlert test, which measures levels of a biomarker for Alzheimer disease in patient urine samples, providing a valuable tool for physicians to diagnose the condition more effectively. The partnership leverages KlinLab's extensive network of hospitals and clinics in the Czech Republic to make the AlzheimAlert test more accessible to patients and healthcare professionals. The European Union has identified Alzheimer's disease as a major healthcare priority, and studies project that the number of people with Alzheimer disease in the United States alone will increase from 4.5 million to 13.2 million by 2050.

Key Takeaways:

  • Nymox Pharmaceutical Corporation has partnered with KlinLab Ltd. to distribute its AlzheimAlert product, a diagnostic test for Alzheimer disease, to physicians in the Czech Republic.
  • AlzheimAlert measures levels of a biomarker for Alzheimer disease in patient urine samples, providing a useful tool for physicians to diagnose the condition.
  • The partnership leverages KlinLab's extensive network of hospitals and clinics in the Czech Republic to increase access to the AlzheimAlert test.
  • The European Union has identified Alzheimer's disease as a major healthcare priority, emphasizing the need for effective diagnostic tools like AlzheimAlert.
  • A recent study projects that the number of people with Alzheimer disease in the United States alone will increase from 4.5 million to 13.2 million by 2050.
  • The annual national direct and indirect costs of caring for Alzheimer patients in the U.S. alone is estimated at $100 billion.
  • Nymox Pharmaceutical Corporation is a biotechnology company focused on developing therapeutics and diagnostics for the unmet needs of the aging population.
  • KlinLab Ltd. offers a range of clinical services and outpatient services to hospitals and clinics throughout the Czech Republic.
  • Nymox recently received CE Mark certification for its AlzheimAlert test kit, making it eligible for sale in the European Union.

Statistics:

  • 4.5 million people in the United States have Alzheimer disease (2023 estimate).
  • The projected number of people with Alzheimer disease in the U.S. will increase to 13.2 million by 2050.
  • 15-20 million people worldwide have Alzheimer disease (estimated).
  • The annual national direct and indirect costs of caring for Alzheimer patients in the U.S. alone is $100 billion.
  • The European Union has identified Alzheimer's disease as a major healthcare priority.

Sources:

  • Nymox Pharmaceutical Corporation (News Release, no date).
  • KlinLab Ltd. (Company Website, no date).
  • World Health Organization (Priority Medicines for Europe and the World, 2004).
  • NewsRx.com (Health & Medicine Week, 2005).
  • National Institute on Aging (Alzheimer's Disease, no date).